Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 10/20 | 0.42 |
| ▸ | NPC1 | O15118 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472433 | 0.90 | NAMPT (0.44) | NAMPTRAB9ANPC1SMN1; SMN2IKBKE | |
| SCHEMBL29284674 | 0.88 | NAMPT (0.40) | NAMPTRAB9ANPC1SMN1; SMN2IKBKE | |
| SCHEMBL19779839 | 0.84 | NAMPT (0.41) | NAMPTRAB9ANPC1SMN1; SMN2IKBKE | |
| SCHEMBL13731080 | 0.83 | NAMPT (0.41) | NAMPTRAB9ANPC1SMN1; SMN2IKBKE | |
| SCHEMBL15472431 | 0.77 | NAMPT (0.44) | NAMPTRAB9ANPC1SMN1; SMN2IKBKE | |
| SCHEMBL16973433 | 0.74 | KMT2A (0.40) | RAB9ANPC1 | |
| SCHEMBL16660714 | 0.74 | TRPV4 (0.45) | NAMPTRAB9ANPC1SMN1; SMN2IKBKE | |
| SCHEMBL29284652 | 0.74 | MAPT (0.39) | RAB9ANPC1PSMB5HPGD | |
| SCHEMBL433546 | 0.73 | RAB9A (0.46) | NAMPTRAB9ANPC1SMN1; SMN2IKBKE | |
| SCHEMBL16660711 | 0.73 | TRPV4 (0.46) | NAMPTRAB9ANPC1SMN1; SMN2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353832-A1 | PROCESS FOR THE PREPARATION OF AMINOPYRIDAZINE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2025-11-20 | — | — | US | disclosed |
| EP-4602033-A1 | PROCESS FOR THE PREPARATION OF AMINOPYRIDAZINE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2025-08-20 | — | — | EP | disclosed |
| CN-120019046-A | Process for preparing aminopyridazine derivatives | 安道麦马克西姆有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024079733-A1 | PROCESS FOR THE PREPARATION OF AMINOPYRIDAZINE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353832-A1 | PROCESS FOR THE PREPARATION OF AMINOPYRIDAZINE DERIVATIVES | CYP3A5, CYP3A4, CYP4Z1 | NAMPT 752/4885RAB9A 2960/4885NPC1 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.